ArticleThe Journal of experimental medicine2005
Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 76 citations in OpenAlex.
- FTY720 requires vitamin BCell reports · 2023Article
- Article
- Platelets and the Role of P2X Receptors in Nociception, Pain, Neuronal Toxicity and Thromboinflammation.International journal of molecular sciences · 2022Review
- An Insight into Recent Advances on Platelet Function in Health and Disease.International journal of molecular sciences · 2022Review
- CAQK, a peptide associating with extracellular matrix components targets sites of demyelinating injuries.Frontiers in cellular neuroscience · 2022Article
- A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis.International journal of molecular sciences · 2021Article
- Platelets in Multiple Sclerosis: Early and Central Mediators of Inflammation and Neurodegeneration and Attractive Targets for Molecular Imaging and Site-Directed Therapy.Frontiers in immunology · 2021Review
- Eomesodermin in CD4International journal of biological sciences · 2021Article
- Platelet-Activating Factor Deteriorates Lysophosphatidylcholine-Induced Demyelination Via Its Receptor-Dependent and -Independent Effects.Molecular neurobiology · 2020Article
- Platelets as Mediators of Neuroinflammation and Thrombosis.Frontiers in immunology · 2020Review
- Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases.Molecular neurobiology · 2017Review
- Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease.Journal of neuroinflammation · 2017Article
- Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection.International journal of molecular sciences · 2017Review
- Characterization of the Phospholipid Platelet-Activating Factor As a Mediator of Inflammation in Chickens.Frontiers in veterinary science · 2017Article
- The Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune Disorders.International journal of molecular sciences · 2016Review
- Platelet Activating Factor Enhances Synaptic Vesicle Exocytosis Via PKC, Elevated Intracellular Calcium, and Modulation of Synapsin 1 Dynamics and Phosphorylation.Frontiers in cellular neuroscience · 2015Article
- Modeling of eicosanoid fluxes reveals functional coupling between cyclooxygenases and terminal synthases.Biophysical journal · 2014Article
- G protein-coupled receptors as therapeutic targets for multiple sclerosis.Cell research · 2012Review
- The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids.Frontiers in pharmacology · 2012Article
- Srf1 is a novel regulator of phospholipase D activity and is essential to buffer the toxic effects of C16:0 platelet activating factor.PLoS genetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental allergic encephalomyelitis (EAE) serves as a model for multiple sclerosis and is considered to be a CD4+ Th1 cell-mediated autoimmune disease. To investigate the role of platelet-activating factor (PAF) in this disease, PAF receptor (PAFR) KO (PAFR-KO) and wild-type (WT) mice, on a C57BL/6 genetic background, were immunized with myelin oligodendrocyte glycoprotein 35-55. The levels of PAF production and PAFR mRNA expression in the spinal cord (SC) correlated with the EAE symptoms. PAFR-KO mice showed lower incidence and less severe symptoms in the chronic phase of EAE than WT mice. However, no difference was observed in T cell proliferation, Th1-cytokine production, or titer of IgG2a between both genotypes. Before onset, as revealed by microarray analysis, mRNAs of inflammatory mediators and their receptors-including IL-6 and CC chemokine receptor 2-were down-regulated in the SC of PAFR-KO mice compared with WT mice. Moreover, in the chronic phase, the severity of inflammation and demyelination in the SC was substantially reduced in PAFR-KO mice. PAFR-KO macrophages reduced phagocytic activity and subsequent production of TNF-alpha. These results suggest that PAF plays a dual role in EAE pathology in the induction and chronic phases through the T cell-independent pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.